Phase 2 Macular Degeneration Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 60 years old or older
- You have been diagnosed with geographic atrophy (GA) caused by age-related macular degeneration (AMD)
- The vision in your study eye (the eye being treated) meets specific vision test score ranges depending on which part of the trial you are joining (confirm with trial site)
- The area of vision loss in your study eye falls within a specific size range, depending on which part of the trial you are joining; if you have multiple affected areas, at least one must be above a minimum size (confirm with trial site)
Who may not be able to join:
- Your GA is caused by something other than AMD
- You have abnormal blood vessel growth in the study eye, or have ever been treated with certain injections (anti-VEGF) in that eye
- You have any eye condition, treatment, or surgery history that could affect vision improvement or interfere with the study assessments (confirm with trial site)
- You are currently using, or have used in the past 12 months, any medication that targets a part of the immune system called the complement system
- You have used certain steroid treatments in or around the study eye within specific time periods before joining (confirm with trial site)
- You have had certain laser, light-based, or heat-based treatments in the study eye
- You had an active eye infection in the study eye within the past 6 months
- You currently have an active infection in or around either eye
- You have glaucoma in the study eye that is active and not well controlled
- You have ever had inflammation inside the eye (uveitis) or of the outer eye wall (scleritis) in either eye
- You have previously received gene therapy in either eye
- You have a serious ongoing health condition that would make it difficult to follow the trial schedule and requirements
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 800-633-1610
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
3 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Incidence and severity of ocular and non-ocular treatment-emergent adverse events (TEAEs); Incidence and severity of ocular and non-ocular treatment-emergent serious adverse events (TESAEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.